In Vitro: BAPTA (0.3-30 μM; 1 h) can be used for the prevention of [Ca2+]-induced cell damage, but disturbe calcium signalling in isingle differentiated NH15-CA2 neuroblastoma and glioma hybrid cells. BAPTA (0-10 mM) inhibits phospholipase C (PLC) activity in a dose-dependent manner, and is unrelated to Ca2+.